{
    "clinical_study": {
        "@rank": "94365", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the increase in spine bone mineral density\n      that has been generally observed in previous clinical studies involving the study drug can\n      be maintained or even increased if followed with raloxifene HCl.  All qualifying study\n      participants will receive the study drug followed by treatment with raloxifene HCl or\n      placebo.  All study participants will receive raloxifene HCl in the third phase of the\n      study."
        }, 
        "brief_title": "Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis", 
        "completion_date": {
            "#text": "July 2005", 
            "@type": "Actual"
        }, 
        "condition": "Osteoporosis, Postmenopausal", 
        "condition_browse": {
            "mesh_term": [
                "Osteoporosis", 
                "Osteoporosis, Postmenopausal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be diagnosed with osteoporosis\n\n          -  Must be female, age 55 through 80\n\n          -  Must be at least 5 years postmenopausal\n\n          -  Must be free of other severe or chronically    disabling conditions\n\n          -  Must be able to properly use injection device.\n\n        Exclusion Criteria:\n\n          -  Must not have bone diseases other than osteoporosis\n\n          -  Must not have history of certain cancers\n\n          -  Must not have certain medical diseases (inflammatory bowel disease, malabsorption\n             syndrome, kidney or bladder stones, venous thrombi or emboli, recent vaginal bleeding\n             due to unknown causes)\n\n          -  Must not have treatment with particular medications (warfarin, estrogens, androgens,\n             steroids, calcitonins, fluorides, biphosphonates)\n\n          -  Must not have known allergy to the study agent or raloxifene HCl"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": "330", 
        "firstreceived_date": "May 2, 2002", 
        "id_info": {
            "nct_id": "NCT00035256", 
            "org_study_id": "5490", 
            "secondary_id": "B3D-MC-GHBQ"
        }, 
        "intervention": [
            {
                "intervention_name": "teriparatide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "raloxifene HCl", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Teriparatide", 
                "Raloxifene"
            ]
        }, 
        "lastchanged_date": "May 11, 2007", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Maywood", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitchener", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sainte -Foy", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "official_title": "Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_outcome": {
            "measure": "The study is designed to compare the effect of 1 year of raloxifene treatment with the effect of placebo on maintaining teriparatide-induced increases in spine and hip BMD."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035256"
        }, 
        "secondary_outcome": [
            {
                "measure": "An open-label treatment phase will extend the study for 1 year beyond the primary endpoint. During this final year of the study all patients will receive raloxifene."
            }, 
            {
                "measure": "The purpose of lengthening is to assess the differences in response to raloxifene when it is administered immediately following versus 1 year after(with and without a washout period) withdrawal from teriparatide."
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2007"
    }, 
    "geocoordinates": {
        "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician": "46.773 -71.276"
    }
}